Skip Navigation
Search Menu
Find a Doctor


Photo of Dr. Kelly Dooley

Kelly Elise Dooley, M.D., M.P.H., Ph.D.

Associate Professor of Medicine

Female  | Languages: English, French

Appointment Phone


Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »


  • Associate Professor of Medicine
  • Associate Professor of Pharmacology and Molecular Sciences

Centers & Institutes



The Johns Hopkins Hospital

Appointment Phone: 410-955-3100

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map

Johns Hopkins Outpatient Center

Appointment Phone: 410-955-3100

601 N. Caroline Street
Baltimore, MD 21287 map

Contact for Research Inquiries

600 N. Wolfe Street
Osler 508
Baltimore, MD 21287 map
Phone: 410-287-0517
Fax: 410-614-9978


Infectious Disease

Research Interests

Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV; Clinical pharmacology of anti-infective agents


Dr. Kelly Dooley is an associate professor of medicine at the Johns Hopkins University School of Medicine. She also holds an appointment in pharmacology and molecular sciences. Her areas of clinical expertise include infectious disease.

Dr. Dooley earned her M.D. from Duke University and her Ph.D. from the Johns Hopkins Bloomberg School of Public Health. She completed her residency and performed a fellowship in infectious diseases at Johns Hopkins.

She has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics, with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is principal investigator or protocol chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB. She’s also involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women. 

Dr. Dooley serves as a firm faculty leader for the Osler Medical Housestaff Training Program. more

    Additional Information

  • Education +


    • Duke University School of Medicine / MD (1999)


    • Johns Hopkins University School of Medicine / Internal Medicine (2002)


    • Johns Hopkins University School of Medicine / Infectious Diseases (2009)


    • American Board of Internal Medicine / Infectious Disease (2007)
    • American Board of Internal Medicine / Internal Medicine (2002)
  • Research & Publications +

    Research Summary

    Dr. Dooley’s research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs, including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

    Selected Publications View all on PubMed

    Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7. doi: 10.1128/AAC.00191-13. Epub 2013 Apr 9.

    Svensson EM, Dooley KE, Karlsson MO. "Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection." Antimicrob Agents Chemother. 2014 Nov;58(11):6406-12. doi: 10.1128/AAC.03246-14. Epub 2014 Aug 11.

    Svensson EM, Murray S, Karlsson MO, Dooley KE. "Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug." J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.

    Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503.

    Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; the TSHEPISO Study Team. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. J Infect Dis. 2014 Jul 31. pii: jiu429. [Epub ahead of print] PMID: 25081933

    Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group (ACTG) A5306 Study Team. Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Anti-Tuberculosis Drug PA-824 with Concomitant Lopinavir/Ritonavir, Efavirenz, or Rifampin. Antimicrob Agents Chemother. 2014 Jun 23. pii: AAC.03332-14. [Epub ahead of print] PMID: 24957823

    Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10. PMID: 24614383 [PubMed - in process]

    Cherkaoui I, Sabouni R, Ghali I, Kizub D, Billioux AC, Bennani K, Bourkadi JE, Benmamoun A, Lahlou O, Aouad RE, Dooley KE. Treatment default amongst patients with tuberculosis in urban Morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results. PLoS One. 2014 Apr 3;9(4):e93574. doi: 10.1371/journal.pone.0093574. eCollection 2014. PMID: 24699682 [PubMed - in process]

    Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23. PMID: 24060875

  • Academic Affiliations & Courses +

    Graduate Program Affiliation

    Pharmacology and Molecular Sciences

  • Activities & Honors +

    Professional Activities

    • Firm Faculty Leader (Janeway Firm), Osler Medical Housestaff Training Program, Johns Hopkins, Baltimore, MD
    • Task Force on Women's Academic Careers in Medicine, Johns Hopkins Department of Medicine, Baltimore, MD, 2012 - 2013
  • Videos & Media +
Is This You? Edit Profile